Page 259 - 2021_07-Haematologica-web

Letters to the Editor
Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 3Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA; 4Hong Kong Children’s Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, China; 5Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 6Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan; 7Hematology/Oncology Division, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital Mahidol University, Thailand; 8Department of Hematology and Oncology, Women and Children's Medical Center, Guangzhou, China; 9Division of Pediatric Hematology-Oncology, Mackay Children's Hospital and Mackay Memorial Hospital, Taipei, Taiwan; 10Department of Pediatrics, University of Malaya Medical Center, Kuala Lumpur, Malaysia; 11Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan; 12Department of Pediatrics, Juntendo University, School of Medicine, Tokyo, Japan; 13Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kawasaki, Japan; 14Department of Hematology and Oncology, Miyagi Children’s Hospital, Sendai, Japan; 15Department of Pediatrics, Nippon Medical School, Tokyo, Japan; 16Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan; 17Department of Hematology and Oncology, Chiba Children’s Hospital, Chiba, Japan; 18Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan; 19Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan; 20Department of Pediatrics, Toho University School of Medicine, Tokyo, Japan; 21Department of Pediatrics, Mie University, Tsu, Mie, Japan; 22Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 23Department of Transplantation and Cell Therapy, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan; 24Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo, Japan and 25Department of Pediatrics, University of Tokyo, Tokyo, Japan.
Correspondence:
MOTOHIRO KATO - katom-tky@umin.ac.jp
doi:10.3324/haematol.2020.266320
Received: July 8, 2020.
Accepted: January 18, 2021. Pre-published: January 28, 2021.
Disclosures: no conflicts of interest to disclose
Contributions: MK is the principal investigator and takes primary responsibility for the paper—he designed this study, interpreted data, wrote the manuscript, and gave final approval; YT, AY, TM, RN, AM, and JJY collected, analyzed and interpreted data, and wrote the manuscript; CKL, K Kudo, YA, JB, HCL, HA, ZC, SK, DH, JF,
DK, KKondoh, AS, TU, M., YTaneyama, MH, MT, AO, EI, KKoh, and HH evaluated patients and collected data; all authors dis- cussed the results and critically reviewed the manuscript.
Acknowledgements: the authors would like to thank Ms. Etsuko Mochizuki for her technical assistance. The authors wish to thank the medical editor from the Department of Education for Clinical Research of the National Center for Child Health and Development for editing this manuscript.
Funding: this research was supported by a grant from the NIH (R01GM118578), by AMED under grant numbers JP20ck0106467, and JP20kk0305014, and by the Japan Society for the Promotion of Science (JSPS) through a Grant-in-Aid for Scientific Research (grant numbers 17K10129 and 18K07836).
References
1. Kato M, Manabe A. Treatment and biology of pediatric acute lym- phoblastic leukemia. Pediatr Int. 2018;60(1):4-12.
2.Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for thiop- urine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105.
3. Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235-1242.
4. Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymor- phisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367-373.
5. Valerie NC, Hagenkort A, Page BD, et al. NUDT15 hydrolyzes 6- thio-deoxyGTP to mediate the anticancer efficacy of 6-thioguanine. Cancer Res. 2016;76(18):5501-5511.
6. Tsujimoto S, Osumi T, Uchiyama M, et al. Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lym- phoid neoplasms. Leukemia. 2018;32(12):2710-2714.
7. Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lym- phoblastic leukaemia. Br J Haematol. 2015;171(1):109-115.
8. Sutiman N, Chen S, Ling KL, et al. Predictive role of NUDT15 vari- ants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. Pharmacogenomics. 2018;19(1):31-43.
9. Schaeffeler E, Jaeger SU, Klumpp V, et al. Impact of NUDT15 genet- ics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med. 2019;21(9):2145-2150.
10. Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017-1020.
11. Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their rela- tion to 6MP toxicity in north Indian children with acute lymphoblas- tic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341-348.
12.Nishii R, Moriyama T, Janke LJ, et al. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018;131(22):2466-2474.
haematologica | 2021; 106(7)
2029